CLAIMS

We claim:

1. A compound represented by the formula I:



I

wherein:

Y is –NH-, -O-, -S-, or –CH_2-;

Z is -O-, -S-, or -N-;

R^{14} is a C_1-C_6 alkyl, C_1-C_6 alkylamino, C_1-C_6 alkylhydroxy, C_3-C_{10} cycloalkylamino, or methylureido group;

R^{15} and R^{17} are independently H, halo, or a C_1-C_6 alkyl group unsubstituted or substituted by one or more R^5 groups;

R^{16} is H or a C_1-C_6 alkyl group when Z is N, and R^{16} is absent when Z is –O- or –S-;

R^{11} is H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, -$C(O)NR^{12}R^{13}$, -$C(O)(C_6$-C_{10} aryl), -$(CH_2)_t(C_6$-C_{10} aryl), -$(CH_2)_t$(5 to 10 membered heterocyclic), -$(CH_2)_tNR^{12}R^{13}$, -$SO_2NR^{12}R^{13}$ or -CO_2R^{12}, wherein said C_1-C_6 alkyl, -$C(O)(C_6$-C_{10} aryl), -$(CH_2)_t(C_6$-C_{10} aryl), and -$(CH_2)_t$(5 to 10 membered heterocyclic) moieties of the said R^{11} groups are unsubstituted or substituted by one or more R^5 groups;

each R^5 is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, -$C(O)R^8$, -$C(O)OR^8$, -$OC(O)R^8$, -$OC(O)OR^8$, -$NR^6C(O)R^7$, -$C(O)NR^6R^7$, -NR^6R^7, -OR^9, -$SO_2NR^6R^7$, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_1-C_6 alkylamino, -$(CH_2)_jO(CH_2)_qNR^6R^7$, -$(CH_2)_tO(CH_2)_qOR^9$, -$(CH_2)_tOR^9$, -$S(O)_j(C_1$-C_6 alkyl), -$(CH_2)_t(C_6$-C_{10} aryl), -$(CH_2)_t$(5 to 10 membered heterocyclic), -$C(O)(CH_2)_t(C_6$-C_{10} aryl), -$(CH_2)_tO(CH_2)_j(C_6$-C_{10} aryl), -$(CH_2)_tO(CH_2)_q$(5 to 10 membered heterocyclic), -$C(O)(CH_2)_t$(5 to 10 membered heterocyclic), -$(CH_2)_jNR^7(CH_2)_qNR^6R^7$, -$(CH_2)_jNR^7CH_2C(O)NR^6R^7$, -$(CH_2)_jNR^7(CH_2)_qNR^9C(O)R^8$, $(CH_2)_jNR^7(CH_2)_tO(CH_2)_qOR^9$, -$(CH_2)_jNR^7(CH_2)_qS(O)_j(C_1$-$C_6$ alkyl), -$(CH_2)_jNR^7(CH_2)_tR^6$, -$SO_2(CH_2)_t(C_6$-C_{10} aryl), and -$SO_2(CH_2)_t$(5 to 10 membered heterocyclic), the -$(CH_2)_q$- and -$(CH_2)_t$- moieties of the said R^5 groups optionally include a carbon-carbon double or triple bond, and the alkyl, aryl and heterocyclic moieties of the said R^5 groups are unsubstituted or substituted with one or more substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -OH, -$C(O)R^8$, -$C(O)OR^8$, -$OC(O)R^8$,

$-OC(O)OR^8$, $-NR^6C(O)R^7$, $-C(O)NR^6R^7$, $-(CH_2)_tNR^6R^7$, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, $-(CH_2)_t(C_6$-C_{10} aryl), $-(CH_2)_t$(5 to 10 membered heterocyclic), $-(CH_2)_tO(CH_2)_qOR^9$, and $-(CH_2)_tOR^9$;

each R^6 and R^7 is independently selected from H, OH, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, $-(CH_2)_t(C_6$-C_{10} aryl), $-(CH_2)_t$(5 to 10 membered heterocyclic), $-(CH_2)_tO(CH_2)_qOR^9$, $-(CH_2)_tCN(CH_2)_tOR^9$, $-(CH_2)_tCN(CH_2)_tR^9$ and $-(CH_2)_tOR^9$, and the alkyl, aryl and heterocyclic moieties of the said R^6 and R^7 groups are unsubstituted or substituted with one or more substituents independently selected from hydroxy, halo, cyano, nitro, trifluoromethyl, azido, $-C(O)R^8$, $-C(O)OR^8$, $-CO(O)R^8$, $-OC(O)OR^8$, $-NR^9C(O)R^{10}$, $-C(O)NR^9R^{10}$, $-NR^9R^{10}$, C_1-C_6 alkyl, $-(CH_2)_t(C_6$-C_{10} aryl), $-(CH_2)_t$(5 to 10 membered heterocyclic), $-(CH_2)_tO(CH_2)_qOR^9$, and $-(CH_2)_tOR^9$, where when R^6 and R^7 are both attached to the same nitrogen, then R^6 and R^7 are not both bonded to the nitrogen directly through an oxygen;

each R^8 is independently selected from H, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, $-(CH_2)_t(C_6$-C_{10} aryl), and $-(CH_2)_t$(5 to 10 membered heterocyclic);

t is an integer from 0 to 6; j is an integer from 0 to 2; q is an integer from 2 to 6;

each R^9 and R^{10} is independently selected from H, $-OR^6$, C_1-C_6 alkyl, and C_3-C_{10} cycloalkyl; and

each R^{12} and R^{13} is independently selected from H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, $-(CH_2)_t(C_3$-C_{10} cycloalkyl), $-(CH_2)_t(C_6$-C_{10} aryl), $-(CH_2)_t$(5 to 10 membered heterocyclic), $-(CH_2)_tO(CH_2)_qOR^9$, and $-(CH_2)_tOR^9$, and the alkyl, aryl and heterocyclic moieties of the said R^{12} and R^{13} groups are unsubstituted or substituted with one or more substituents independently selected from R^5, or R^{12} and R^{13} are taken together with the nitrogen to which they are attached to form a C_5-C_9 azabicyclic, aziridinyl, azetidinyl, pyrrolidinyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, isoquinolinyl, or dihydroisoquinolinyl ring, wherein said C_5-C_9 azabicyclic, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, isoquinolinyl, or dihydroisoquinolinyl rings are unsubstituted or substituted with one or more R^5 substituents, where R^{12} and R^{13} are not both bonded to the nitrogen directly through an oxygen;

or prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds and said prodrugs and said metabolites.

2. A compound, prodrug, metabolite, salt, or solvate according to claim 1, wherein R^{11} is $-(CH_2)_t$(5 to 10 membered heterocyclic), $-C(O)NR^{12}R^{13}$, $-(CH_2)_tNR^{12}R^{13}$, $-SO_2NR^{12}R^{13}$ or $-CO_2R^{12}$.

3. A compound of claim 2, wherein R^{11} is $-(CH_2)_t$(5 to 10 membered heterocyclic), $-C(O)NR^{12}R^{13}$, $-SO_2NR^{12}R^{13}$ or $-CO_2R^{12}$.

4. A compound of claim 3, wherein R^{11} is $-(CH_2)_t$(5 to 10 membered heterocyclic) or $-C(O)NR^{12}R^{13}$.

5. A compound of claim 4, wherein R^{11} is $-C(O)NR^{12}R^{13}$, wherein R^{12} and R^{13} are independently selected from H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, $-(CH_2)_t(C_3$-C_{10} cycloalkyl), $-(CH_2)_t(C_6$-C_{10} aryl), $-(CH_2)_t$(5 to 10 membered heterocyclic), $-(CH_2)_tO(CH_2)_qOR^9$, and $-(CH_2)_tOR^9$.

6. A compound of claim 5, wherein R^{11} is $-C(O)NR^{12}R^{13}$, and wherein R^{12} and R^{13} are taken together with the nitrogen to which they are attached to form a C_5-C_9 azabicyclic, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, isoquinolinyl, or dihydroisoquinolinyl ring, wherein said C_5-C_9 azabicyclic, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, isoquinolinyl, or dihydroisoquinolinyl ring is unsubstituted or substituted by 1 to 5 R^5 substituents.

7. A compound of claim 6, wherein R^{12} and R^{13} are taken together with the nitrogen to which they are attached to form a pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, isoquinolinyl, or dihydroisoquinolinyl ring, wherein said pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, isoquinolinyl, or dihydroisoquinolinyl ring is unsubstituted or substituted with 1 to 5 R^5 substituents.

8. A compound of claim 7, wherein R^{12} and R^{13} are taken together with the nitrogen to which they are attached to form a pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl ring, wherein said pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl ring is unsubstituted or substituted with 1 to 5 R^5 substituents.

9. A compound of claim 8, wherein R^{12} and R^{13} are taken together with the nitrogen to which they are attached to form a pyrrolidinyl or piperidinyl ring, wherein said pyrrolidinyl or piperidinyl ring is unsubstituted or substituted with 1 to 5 R^5 substituents.

10. A compound of claim 9, wherein R^{12} and R^{13} are taken together with the nitrogen to which they are attached to form a pyrrolidinyl ring, wherein said pyrrolidinyl is unsubstituted or substituted with 1 to 5 R^5 substituents.

11. A compound of claim 10, wherein R^{12} and R^{13} are taken together with the nitrogen to which they are attached to form a pyrrolidin-1-yl ring, wherein said pyrrolidin-1-yl ring is unsubstituted or substituted with 1 to 5 R^5 substituents.

12. A compound of claim 4, wherein R^{11} is a $-(CH_2)_t$(5 to 10 membered heterocyclic) group unsubstituted or substituted with 1 to 5 R^5 groups.

13. A compound of claim 12, wherein R^{11} is a $-(CH_2)_t$(5-8 membered heterocyclic) group unsubstituted or substituted with 1 to 5 R^5 groups.

14. A compound of claim 13, wherein R^{11} is a $-(CH_2)_t$(5 or 6 membered heterocyclic) group is unsubstituted or substituted with 1 to 5 R^5 groups.

15. A compound of claim 14, wherein R^{11} is a $-(CH_2)_t$(5 membered heterocyclic) group unsubstituted or substituted with 1 to 5 R^5 groups.

16. A compound of claim 15, wherein R^{11} is a thiazolyl, unsubstituted or substituted by 1 to 5 R^5 groups.

17. A compound of claim 15, wherein R^{11} is an imidazolyl, unsubstituted or substituted by 1 to 5 R^5 groups.

18. A compound of claim 1, wherein R^{16} is a C_1-C_6 alkyl group.

19. A compound of claim 18, wherein R^{16} is methyl.

20. A compound of claim 1, wherein R^{14} is methyl.

21. A compound represented by the formula II:



II

wherein:

Z is -O-, -S-, or -N- ;

R^{14} is a C_1-C_6 alkyl, C_1-C_6 alkylamino, C_1-C_6 alkylhydroxy, C_3-C_{10} cycloalkylamino, or methylureido group;

R^{15} and R^{17} are independently H, halo, or a C_1-C_6 alkyl group;

R^{16} is H or a C_1-C_6 alkyl group when Z is –N- and R^{16} is absent when Z is –O- or –S-;

R^{11} is a heteroaryl group unsubstituted or substituted by one or more halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, $-C(O)R^8$, $-C(O)OR^8$, $-OC(O)R^8$, $-OC(O)OR^8$, $-NR^6C(O)R^7$, $-C(O)NR^6R^7$, $-NR^6R^7$, $-OR^9$, $-SO_2NR^6R^7$, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, $-(CH_2)_jO(CH_2)_qNR^6R^7$, $-(CH_2)_tO(CH_2)_qOR^9$, $-(CH_2)_tOR^9$, $-S(O)_j(C_1$-C_6 alkyl), $-(CH_2)_t(C_6$-C_{10} aryl), $-(CH_2)_t$(5 to 10 membered heterocyclic), $-C(O)(CH_2)_t(C_6$-C_{10} aryl), $-(CH_2)_tO(CH_2)_j(C_6$-C_{10} aryl), $-(CH_2)_tO(CH_2)_q$(5 to 10 membered heterocyclic), $-C(O)(CH_2)_t$(5 to 10 membered heterocyclic), $-(CH_2)_jNR^7(CH_2)_qNR^6R^7$, $-(CH_2)_jNR^7CH_2C(O)NR^6R^7$, $-(CH_2)_jNR^7(CH_2)_qNR^9C(O)R^8$, $-(CH_2)_jNR^7(CH_2)_tO(CH_2)_qOR^9$, $-(CH_2)_jNR^7(CH_2)_qS(O)_j(C_1$-$C_6$ alkyl), $-(CH_2)_jNR^7$ $-(CH_2)_tR^6$, $-SO_2(CH_2)_t(C_6$-C_{10} aryl), and $-SO_2(CH_2)_t$(5 to 10 membered heterocyclic), the $-(CH_2)_q$- and $-(CH_2)_t$- moieties of the said R^5 groups optionally include a carbon-carbon double or triple bond, and the alkyl, aryl and heterocyclic moieties of the said R^5 groups are unsubstituted or substituted with one or more substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -OH, $-C(O)R^8$, $-C(O)OR^8$, $-OC(O)R^8$, $-OC(O)OR^8$, $-NR^6C(O)R^7$, $-C(O)NR^6R^7$, $-(CH_2)_tNR^6R^7$, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, $-(CH_2)_t(C_6$-C_{10} aryl), $-(CH_2)_t$(5 to 10 membered heterocyclic), $-(CH_2)_tO(CH_2)_qOR^9$, and $-(CH_2)_tOR^9$;

each R^6 and R^7 is independently selected from H, OH, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, $-(CH_2)_t(C_6$-C_{10} aryl), $-(CH_2)_t$(5 to 10 membered heterocyclic), $-(CH_2)_tO(CH_2)_qOR^9$, $-(CH_2)_tCN(CH_2)_tOR^9$, $-(CH_2)_tCN(CH_2)_tR^9$ and $-(CH_2)_tOR^9$, and the alkyl, aryl and heterocyclic moieties of the said R^6 and R^7 groups are unsubstituted or substituted with one or more substituents independently selected from hydroxy, halo, cyano, nitro, trifluoromethyl, azido, $-C(O)R^8$, $-C(O)OR^8$, $-CO(O)R^8$, $-OC(O)OR^8$, $-NR^9C(O)R^{10}$, $-C(O)NR^9R^{10}$, $-NR^9R^{10}$, C_1-C_6 alkyl, $-(CH_2)_t(C_6$-C_{10} aryl), $-(CH_2)_t$(5 to 10 membered heterocyclic), $-(CH_2)_tO(CH_2)_qOR^9$, and $-(CH_2)_tOR^9$, where when R^6 and R^7 are both attached to the same nitrogen, then R^6 and R^7 are not both bonded to the nitrogen directly through an oxygen;

each R^8 is independently selected from H, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, $-(CH_2)_t(C_6$-C_{10} aryl), and $-(CH_2)_t$(5 to 10 membered heterocyclic);

each R^9 and R^{10} is independently selected from H, C_1-C_6 alkyl, and C_3-C_{10} cycloalkyl;

t is an integer from 0 to 6; j is an integer from 0 to 2; q is an integer from 2 to 6;

or prodrugs or metabolites thereof, pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, or said metabolites.

22. A compound of claim 21, R^{16} is a C_1-C_6 alkyl group.

23. A compound of claim 22, R^{16} is methyl.

24. A compound of claim 21, wherein R^{14} is methyl.

25. A compound represented by the formula **III**:



III

wherein:

R^{14} is a C_1-C_6 alkyl, C_1-C_6 alkylamino, C_1-C_6 alkylhydroxy, C_3-C_{10} cycloalkylamino, or methylureido group;

R^{15} and R^{17} are independently H, halo, or a C_1-C_6 alkyl group; and

R^{11} is a heterocyclic or a heteroaryl group unsubstituted or substituted by one or more groups selected from $-C(O)OR^8$, C_1-C_6 alkyl, and $-(CH_2)_tOR^9$;

each R^8 is independently selected from H, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, $-(CH_2)_t(C_6$-C_{10} aryl), and $-(CH_2)_t$(5 to 10 membered heterocyclic);

each R^9 is independently selected from H, C_1-C_6 alkyl, and C_3-C_{10} cycloalkyl; and

t is an integer from 0 to 6; j is an integer from 0 to 2; q is an integer from 2 to 6;

or prodrugs or metabolites thereof, pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites.

26. A compound of claim 25, wherein R^{14} is methyl.

27. A compound represented by the formula **IV**:



IV

wherein:

R^{14} is a C_1-C_6 alkyl, C_1-C_6 alkylamino, C_1-C_6 alkylhydroxy, C_3-C_{10} cycloalkylamino, or methylureido group;

R^{15} and R^{17} are independently H, halo, or a C_1-C_6 alkyl group;

R^{11} is a heterocyclic or a heteroaryl group unsubstituted or substituted by one or more groups selected from $-C(O)OR^8$, C_1-C_6 alkyl, and $-(CH_2)_tOR^9$;

each R^8 is independently selected from H, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, $-(CH_2)_t(C_6$-C_{10} aryl), and $-(CH_2)_t$(5 to 10 membered heterocyclic);

each R^9 is independently selected from H, C_1-C_6 alkyl, and C_3-C_{10} cycloalkyl; and

t is an integer from 0 to 6; j is an integer from 0 to 2; q is an integer from 2 to 6;

or prodrugs or metabolites thereof, pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites.

28. A compound of claim 27, wherein R^{14} is methyl.

29. A compound of claim 1 wherein said compound is selected from the group consisting of:



;



;



;



;


O
N
H
O
S
S
O
N
MeO
OMe

;


O
N
H
O
S
N
N

;


O
N
H
O
S
S
O
N
HO
OH

;


O
N
H
O
S
S
O
N
HO

;


O
N
H
O
S
S
O
N
HO

;


O
N
H
O
S
N
N

;


H
N
O
O
S
S
O
N
MeO

;


O
N
H
O
S
O
O
N
MeO

;


O
N
H
O
S
O
N
N

;


O
NH
O
S
O
N
MeO

;


;

;


;

;


;

;


;

;


; and

;

or prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites.

30. A pharmaceutical composition for the treatment of a hyperproliferative disorder in a mammal comprising a therapeutically effective amount of a compound, prodrug, metabolite, salt or solvate of claim 1 and a pharmaceutically acceptable carrier.

31. The pharmaceutical composition of claim 30, wherein said hyperproliferative disorder is cancer.

32. The pharmaceutical composition of claim 31, wherein said cancer is brain, lung, kidney, renal, ovarian, ophthalmic, squamous cell, bladder, gastric, pancreatic, breast, head, neck, oesophageal, gynecological, prostate, colorectal or thyroid cancer.

33. The pharmaceutical composition of claim 30, wherein said hyperproliferative disorder is noncancerous.

34. The pharmaceutical composition of claim 33, wherein said hyperproliferative disorder is a benign hyperplasia of the skin or prostate.

35. A pharmaceutical composition for the treatment of a hyperproliferative disorder in a mammal comprising a therapeutically effective amount of a compound, prodrug, metabolite, salt or solvate of claim 1 in combination with an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, and anti-androgens, and a pharmaceutically acceptable carrier.

36. A pharmaceutical composition for the treatment of pancreatitis or kidney disease in a mammal comprising a therapeutically effective amount of a compound, prodrug, metabolite, salt or solvate of claim 1 and a pharmaceutically acceptable carrier.

37. A pharmaceutical composition for the prevention of blastocyte implantation in a mammal comprising a therapeutically effective amount of a compound, prodrug, metabolite, salt or solvate of claim 1 and a pharmaceutically acceptable carrier.

38. A pharmaceutical composition for treating a disease related to vasculogenesis or angiogenesis in a mammal comprising a therapeutically effective amount of a compound, prodrug, metabolite, salt or solvate of claim 1 and a pharmaceutically acceptable carrier.

39. The pharmaceutical composition of claim 38 wherein said disease is selected from the group consisting of tumor angiogenesis, chronic inflammatory disease, atherosclerosis, skin diseases, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.

40. A pharmaceutical composition for treating a disease related to vasculogenesis or angiogenesis in a mammal comprising a therapeutically effective amount of a compound, prodrug, metabolite, salt or solvate of claim 1, a therapeutically effective amount of a compound, prodrug, metabolite, salt or solvate of an antihypertensive agent, and a pharmaceutically acceptable carrier.

41. A method of treating a hyperproliferative disorder in a mammal comprising administering to said mammal a therapeutically effective amount of a compound, prodrug, metabolite, salt or solvate of claim 1.

42. The method of claim 41 wherein said hyperproliferative disorder is cancer.

43. The method of claim 42 wherein said cancer is brain, lung, ophthalmic, squamous cell, renal, kidney, ovarian, bladder, gastric, pancreatic, breast, head, neck, oesophageal, prostate, colorectal, gynecological or thyroid cancer.

44. The method of claim 41 wherein said hyperproliferative disorder is noncancerous.

45. The method of claim 44 wherein said hyperproliferative disorder is a benign hyperplasia of the skin or prostate.

46. A method for the treatment of a hyperproliferative disorder in a mammal comprising administering to said mammal a therapeutically effective amount of a compound, prodrug, metabolite, salt or solvate of claim 1 in combination with an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, and anti-androgens.

47. A method of treating pancreatitis or kidney disease in a mammal comprising administering to said mammal a therapeutically effective amount of a compound, prodrug, metabolite, salt or solvate of claim 1.

48. A method of preventing blastocyte implantation in a mammal comprising administering to said mammal a therapeutically effective amount of a compound, prodrug, metabolite, salt or solvate of claim 1.

49. A method for treating a disease related to vasculogenesis or angiogenesis in a mammal comprising administering to said mammal a therapeutically effective amount of a compound, prodrug, metabolite, salt or solvate of claim 1.

50. The method of claim 49 wherein said disease is selected from the group consisting of tumor angiogenesis, chronic inflammatory disease, atherosclerosis, skin diseases, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.

51. A method for treating a disease related to vasculogenesis or angiogenesis in a mammal comprising administering to said mammal a therapeutically effective amount of a compound, prodrug, metabolite, salt or solvate of claim 1 in conjunction with a therapeutically effective amount of an anti-hypertensive agent.